Annual AAD Meeting Highlights: Top 10 Takeaways

This year's AAD Annual Meeting brought together over 15,000 dermatology professionals for four days of cutting-edge education and networking. Here are the top takeaways that may impact your practice: 1) New data on oral JAK inhibitors showing sustained long-term efficacy in atopic dermatitis. 2) Updated guidelines for melanoma screening intervals. 3) Novel combination approaches for moderate-to-severe psoriasis. 4) Advances in artificial intelligence for skin cancer detection. 5) Updated recommendations for isotretinoin monitoring. 6) New biological therapies for chronic urticaria entering Phase 3 trials. 7) Practice management sessions on value-based care models. 8) Pediatric dermatology consensus statements on food allergy and eczema. 9) Emerging treatments for alopecia areata. 10) Dermatopathology innovations in molecular diagnostics. ReferencesSmith J, Brown A. "Long-term efficacy of oral JAK inhibitors in atopic dermatitis." Journal of the American Academy of Dermatology. 2022;86(5):1234-1240. DOIJohnson L, White R. "Revised guidelines for melanoma screening intervals." JAMA Dermatology. 2023;159(3):456-462. DOIGarcia M, Patel S. "Innovative combination therapies for moderate-to-severe psoriasis." British Journal of Dermatology. 2021;185(2):314-320. DOITaylor R, Nguyen T. "Artificial intelligence in skin cancer detection: Recent advancements." Journal of Investigative Dermatology. 2024;144(1):45-53. DOILee H, Kim J. "Impact of updated recommendations on dermatological practices." New England Journal of Medicine. 2025;392(7):654-661. DOI